Strides Arcolab, US FDA, Polymyxin B, Onco Therapies

BANGALORE: Bangalore-based Strides Arcolab received European and US FDA approval on Friday for two of its products. The US FDA stamp was given for antibacterial drug Polymyxin B that is used for the treatment of infections of the urinary tract and bloodstream.

The drug maker is developing and supplying more than 25 injectable products for the USA market, which will be marketed by Sagent. According to a press statement the 2010 IMS data stated that the U.S. market for injectable Polymyxin B was $8 million.

The European approval was given to Onco Therapies Limited , a division of Agila (a wholly owned subsidiary of Strides Arcolab) for its oral dosage oncology facility in Bangalore. The oncology complex that was set up in 2009 makes injectables and oral products.